Finland resumes use of AstraZeneca's Covid vaccine for people above 65 yrs

Finland has resumed the use of the AstraZeneca Covid-19 vaccine, but only for people over the age of 65, as per the guidelines issued by the Finnish Institute for Health and Welfare

AstraZeneca, pharma, coronavirus, vaccine
AstraZeneca's coronavirus vaccine
IANS Helsinki
2 min read Last Updated : Mar 30 2021 | 1:33 PM IST

Finland has resumed the use of the AstraZeneca Covid-19 vaccine, but only for people over the age of 65, as per the guidelines issued by the Finnish Institute for Health and Welfare (THL).

In a statement on Monday, the THL said that it was still investigating the possibility of side effects of the AstraZeneca vaccine in younger adults, reports Xinhua news agency.

Use of the AstraZeneca vaccine was suspended in Finland on March 19 as a precautionary measure after two individuals were diagnosed with blood clotting after inoculation.

The resumption of the use of the vaccine is based on a statement by Finland's national vaccine expert group that it was safe for use for people aged 65 and older.

The European Medicines Agency (EMA) has also conducted an investigation and said it considers the vaccine safe and effective.

"There is no increased risk of the very rare blood clotting disorder after vaccination in people over 65 years of age, whose possible association with the AstraZeneca vaccine is currently being investigated.

"Vaccinations for this age group can therefore be continued as normal," Taneli Puumalainen, chief physician at the THL, was quoted as saying in the statement.

As a precautionary measure, the AstraZeneca vaccine is not currently administered to people under 65 years of age in the other Nordic countries and in Germany.

The Finnish health authority said that use of the AstraZeneca vaccine for people under the age of 65 may continue after the Easter holiday at the earliest.

To date, more than 180,000 people in Finland have received the AstraZeneca vaccine.

--IANS

ksk/

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :FinlandCoronavirus VaccineAstraZeneca

First Published: Mar 30 2021 | 12:22 PM IST

Next Story